Естония - естонски - Ravimiamet

venipharm - naatriumenoksapariin - süstelahus süstlis - 6000rÜ 0.6ml 24tk; 6000rÜ 0.6ml 2tk; 6000rÜ 0.6ml 30tk; 6000rÜ 0.6ml 20tk; 6000rÜ 0.6ml 6tk; 6000rÜ 0.6ml 12tk

Естония - естонски - Ravimiamet

venipharm - naatriumenoksapariin - süstelahus süstlis - 8000rÜ 0.8ml 2tk; 8000rÜ 0.8ml 12tk; 8000rÜ 0.8ml 10tk; 8000rÜ 0.8ml 1tk; 8000rÜ 0.8ml 24tk; 8000rÜ 0.8ml 30tk; 8000rÜ 0.8ml 50tk; 8000rÜ 0.8ml 6tk

Естония - естонски - Ravimiamet

venipharm - naatriumenoksapariin - süstelahus süstlis - 2000rÜ 0.2ml 20tk; 2000rÜ 0.2ml 6tk; 2000rÜ 0.2ml 1tk; 2000rÜ 0.2ml 10tk; 2000rÜ 0.2ml 50tk; 2000rÜ 0.2ml 2tk

Естония - естонски - Ravimiamet

ideal trade links uab - deksametasoon - tablett - 4mg 28tk; 4mg 56tk; 4mg 100tk

Естония - естонски - Ravimiamet

ideal trade links uab - deksametasoon - tablett - 20mg 10tk; 20mg 50tk; 20mg 30tk; 20mg 20tk

Европейски съюз - естонски - EMA (European Medicines Agency)

novo nordisk a/s - aspartinsuliin - diabeet mellitus - drugs used in diabetes, insulins and analogues for injection, fast-acting - suhkurtõve ravi täiskasvanutel, noorukitel ja 1-aastastel ja vanematel lastel.

Европейски съюз - естонски - EMA (European Medicines Agency)

novo nordisk a/s - insuliini detemir - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõve ravi täiskasvanutel, noorukitel ja 1-aastastel ja vanematel lastel.

Европейски съюз - естонски - EMA (European Medicines Agency)

novo nordisk a/s - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõve ravi.

Европейски съюз - естонски - EMA (European Medicines Agency)

zambon spa - safinamiidmetaansulfonaat - parkinsoni tõbi - parkinsoni tõve ravimid - xadago on näidustatud idiopaatilise parkinsoni tõve (pt) täiskasvanud patsientide ravi ravina levodopa (l-dopa) stabiilsele annusele eraldi või koos muude pd ravimitega kesk-kuni-staadiumis hilisstaadiumis patsientidel.

Европейски съюз - естонски - EMA (European Medicines Agency)

bayer ag - rivaroksabaan - arthroplasty, replacement; venous thromboembolism - antitrombootilised ained - xarelto, co-manustada atsetüülsalitsüülhape (asa) üksi või koos asa pluss clopidogrel või ticlopidine, on näidustatud ennetamine atherothrombotic sündmuste täiskasvanud patsientidel pärast äge koronaarsündroom (acs) kõrgenenud südame biomarkerite. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.